INTERVIEWS MORE INTERVIEWS
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200 we have obtained orphan drug status from FDA for the treatment of liver cancer."
"We produce approximately 7% of the global vanadium supply, and on the titanium side, we are expected to produce about two thirds of the Brazilian demand for titanium pigment once the project reaches full capacity."
"Ontario has one of the highest densities of expertise in underground mining out of any of the jurisdictions we work in."
"For the next 20 years, there will be lots of exploration and development in a region where there are few roads and limited sea access. So, aviation will play a crucial role in the green transition."
ARTICLES
Protecting Supply Chains and Prosperity: The Case for Reducing US Dependency on Foreign Critical Minerals
October 12, 2022
Expert Opinion Article by Eric Mears, Vice President, Haley & Aldrich
Arizona Copper Production: Securing a Domestic Supply Chain
October 10, 2022
Arizona, leading the charge towards the green transition
Presas de Relaves: La Prevención de Fallas Catastróficas y los Principios ESG
July 14, 2022
Guillermo Barreda, General Manager, Knight Piésold Peru
Driving Change: The responsible sourcing of cobalt and other key materials for the EV industry
May 23, 2022
“The low carbon economy will likely require US$50 trillion of investment over the next three decades, making it the biggest purchase order in history.”
NEWS
APLA 2022 Registrations are Open
July 13, 2022
APLA 2021 Registrations are Open
October 27, 2021
APLA Sustainability Virtual Meeting 2021
September 19, 2021
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
